Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tecarfarin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cadrenal Therapeutics Raises $5.1 Million Via Market Facility
    Cadrenal Therapeutics Raises $5.1 Million Via Market Facility

    24 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cadrenal-therapeutics-raises-5-1-million-via-at-the-market-facility-302285248.html

    PR NEWSWIRE
    24 Oct 2024
    Share Share
    Cadrenal And Abbott Collaborate On Tecarfarin For LVAD Patients
    Cadrenal And Abbott Collaborate On Tecarfarin For LVAD Patients

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cadrenal-therapeutics-and-abbott-initiate-collaborative-effort-to-advance-novel-anticoagulant-tecarfarin-for-patients-with-lvads-302214878.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    Cadrenal Engages The Sage Group to Advance Tecarfarin's Late-Stage Development
    Cadrenal Engages The Sage Group to Advance Tecarfarin's Late-Stage Development

    12 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cadrenal-therapeutics-engages-the-sage-group-to-advance-tecarfarins-late-stage-development-and-commercialization-302012016.html

    PR NEWSWIRE
    12 Dec 2023
    Share Share
    Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist
    Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist

    05 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cadrenal-therapeutics-highlights-additional-need-for-a-new-vitamin-k-antagonist-tecarfarin-following-updates-from-the-recent-european-society-of-cardiology-congress-301917398.html

    PR NEWSWIRE
    05 Sep 2023
    Share Share
    Cadrenal Therapeutics Expands Focus for Tecarfarin
    Cadrenal Therapeutics Expands Focus for Tecarfarin

    01 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cadrenal-therapeutics-expands-focus-for-tecarfarin-to-patients-with-implanted-medical-devices-for-heart-diseases-301889909.html

    PR NEWSWIRE
    01 Aug 2023
    Share Share